In a world-first for sports science, OxiDx, a majority-owned subsidiary of ASX-listed biotechnology company Proteomics International has unveiled a groundbreaking, easy-to-use diagnostic tool to detect and monitor muscle damage and recovery in athletes.
Proteomics sees OxiDx’s innovative fingerprick blood test becoming a valuable step in transforming sports medicine, helping to minimise muscle injury, better manage recovery and optimise performance in athletes.